H. Lundbeck  and Prexton Therapeutics have signed a definitive agreement in which Lundbeck will acquire Prexton. Under terms of the agreement, Lundbeck will pay €100 million upfront ($123 million) plus €805 million ($989 million) in development and sales milestones. By acquiring Prexton, Lundbeck will obtain global rights for foliglurax, which currently is in clinical phase…